Morgan Stanley Sticks to Their Buy Rating for Crispr Therapeutics AG (CRSP)
In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), ...
Crispr Therapeutics price target lowered to $30 from $45 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Crispr Therapeutics (CRSP) to $30 from $45 and keeps an Underweight rating on the shares. The ...
Zacks.com on MSN3d
CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $43.42, moving -1.83% from the previous trading session.
FY2024 Earnings Estimate for CRSP Issued By Leerink Partnrs
Leerink Partnrs boosted their FY2024 earnings per share (EPS) estimates for CRISPR Therapeutics in a note issued to investors ...
ETF Daily News3d
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives $78.38 Average Price Target from Analysts
CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has earned a consensus recommendation of “Hold” from the nineteen brokerages that are covering the firm, Marketbeat Ratings reports.
Zacks.com on MSN4d
CRISPR Therapeutics (CRSP) Moves 6.5% Higher: Will This Strength Last?
CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price ...
Nasdaq4d
CRISPR Therapeutics (CRSP) Moves 6.5% Higher: Will This Strength Last?
CRISPR Therapeutics AG (CRSP) shares rallied 6.5% in the last trading session to close at $44.20. This move can be attributable to notable volume with a higher number of shares being traded than ...